An observational study in Osteoarthitis and Osteoporosis, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Peking University People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.
Among the 87 studies in Osteoporosis with a site in China, this one is the 13th largest by planned enrollment of the 30 observational ones that give a count, is one of 2 that started in 2005, is one of 30 observational ones, reaches primary completion later than 21 of the 32 other live ones, and was the 81st registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Sites in China
Ages 45–80 · Women only
Dr. Li Chen · Sites in China
Ages 18+ · Healthy volunteers
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Peking University People's Hospital · Sites in China
Ages 18+ · Healthy volunteers
Wuhan Union Hospital, China · Sites in China
Ages 40+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 160 across 456 observational studies indexed under Osteoporosis.
Median enrollment 120 across the 57 interventional studies, 1,750 across the 30 observational. Of the 33 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 87 have an industry lead sponsor. The 10 most frequent:
Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
Peking University People's Hospital has 3 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Osteoporosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT07895082Phase 3Shanghai University of Traditional Chinese MedicineQuanduzhong Capsules for Primary Osteoporosis | 2027-04-15 |
| NCT07474571Peking University People's HospitalEvaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging | 2026-12-01 |
| NCT07165158The First Affiliated Hospital of Xiamen UniversityThe Effect of Semaglutide on Bone Health | 2026-12-31 |
| NCT06379243The Seventh Affiliated Hospital of Sun Yat-sen UniversityDevelopment and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 87 studies in Osteoporosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Overview This clinical research focuses on the development and validation of a multimodal artificial intelligence (AI) platform designed for the automated diagnosis and precise staging of two major musculoskeletal conditions: Osteoporosis (OP) and Osteoarthritis (OA). By integrating diverse clinical imaging data, the study aims to provide a more objective and standardized approach to assessing bone and joint degeneration.
Technological Core: Intelligent Staging
Traditional diagnosis often relies on manual interpretation, which can lead to inter-observer variability. This study employs deep learning and multimodal imaging to:
For Osteoporosis: Automatically quantify bone mineral density and micro-architectural changes to determine the stage of bone loss and evaluate fracture risk.
For Osteoarthritis: Identify subtle radiological markers such as joint space narrowing and osteophyte formation to categorize the severity of joint degeneration according to international staging standards (e.g., Kellgren-Lawrence scale).
Why This Matters Early Intervention: By identifying early-stage changes in bone density and joint integrity, clinicians can implement preventive treatments before significant disability occurs.
Standardized Care: The intelligent diagnostic model provides a "digital second opinion," ensuring consistent staging across different healthcare settings.
Efficiency: The automated workflow reduces the workload of radiologists while maintaining high diagnostic accuracy.
Ethical Compliance The study is conducted at Peking University People's Hospital under the supervision of the Institutional Review Board (Approval No. 2026PHB097-001). It strictly adheres to international ethical standards, including the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, to ensure patient data privacy and safety.
Study Design and Population The research employs a bidirectional observational cohort study design. Retrospective Cohort (Model Development): Data will be collected from approximately 1,500 patients who visited the Peking University People's Hospital (PKUPH) between November 2005 and November 2025.
Prospective Cohort (External Validation): At least 500 new participants will be recruited starting from December 2025 to test the model's performance in a real-world clinical setting.
The study targets adults aged 18 to 90 who have completed relevant musculoskeletal imaging scans.
Study Population DescriptionThe study population consists of adult patients seeking medical consultation or treatment at the Department of Orthopaedic Trauma, Peking University People's Hospital. This population represents a diverse clinical spectrum of musculoskeletal aging, ranging from healthy skeletal status to various stages of Osteoporosis (OP) and Osteoarthritis (OA).The research employs a bidirectional cohort structure:Retrospective Cohort: Includes approximately 1,500 patients treated between November 2005 and November 2025, primarily used for model training and internal algorithm validation.Prospective Cohort: Includes at least 500 patients recruited starting from December 2025, used for independent external validation of the model's diagnostic accuracy and staging robustness in a real-world clinical setting.Participants are characterized by their availability of multimodal data, including radiological images (X-ray, CT, MRI) and clinical laboratory indicators (e.g., bone tur
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants with osteoarthritis
Other: No Interventions
participants with osteoporosis
Other: No Interventions
participants with osteoarthritis
Other: No Interventions
participants with osteoporosis
Other: No Interventions
participants without osteoporosis and osteoarthritis
Other: No Interventions
participants without osteoporosis and osteoarthritis
Other: No Interventions
No Interventions
Bone age status
Bone mineral density and osteoarthitis
Time frame: From enrollment to the initial treatment at 2 years
Plan to share: No — Privacy and Confidentiality Risks: The study involves sensitive clinical imaging (X-ray, CT, MRI) and laboratory data from patients at Peking University People's Hospital. Even after de-identification, there is a risk that high-resolution medical images could be re-identified, violating patient privacy agreements .Institutional Data Policy: The protocol states that data processing and export are restricted to computers registered within the hospital, and "data does not leave the hospital". This strict internal data management policy is designed to maintain security and hospital-level control over clinical assets.Ethical Constraints: The Institutional Review Board (IRB) approved the study based on strict data protection measures. Sharing raw IPD externally might require additional informed consent from participants or further ethical amendments that were not part of the original approval (2026PHB097-001).Intellectual Property and Proprietary Algorithms: Since this study involves
No publications or documents are linked to this record.
Started Nov 2005 (actual). Primary completion is estimated for Dec 2026, 253 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →